Characterization of rimegepant drug–drug interactions using the cytochrome <scp>P450</scp> probe drugs, itraconazole, rifampin, fluconazole, and midazolam
Based on the magnitude of DDIs, these studies indicate the following: co-administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co-administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co-administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.
Authors
- Richard Bertz (ORCID: https://orcid.org/0009-0006-4593-1310)
- Beth Morris (ORCID: https://orcid.org/0009-0006-4347-2042)
- Robert Croop (ORCID: https://orcid.org/0009-0004-0151-1192)
- Kyle Matschke (ORCID: https://orcid.org/0009-0003-2043-851X)
- Jing Liu (ORCID: https://orcid.org/0000-0002-6730-9198)
- Rajinder Bhardwaj (ORCID: https://orcid.org/0009-0005-2720-2192)
Institutions
- Pfizer (United States) (US)
- Biohaven Pharmaceuticals (United States) (US)
- Certara (United States) (US)
- Integra LifeSciences (United States) (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1111/head.14836
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- Pfizer